Logo image of GUTS

FRACTYL HEALTH INC (GUTS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GUTS - US35168W1036 - Common Stock

2.37 USD
+0.1 (+4.41%)
Last: 12/29/2025, 8:00:02 PM
2.32 USD
-0.05 (-2.11%)
After Hours: 12/29/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, GUTS scores 2 out of 10 in our fundamental rating. GUTS was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of GUTS have multiple concerns. GUTS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GUTS has reported negative net income.
GUTS had a negative operating cash flow in the past year.
GUTS had negative earnings in each of the past 5 years.
In the past 5 years GUTS always reported negative operating cash flow.
GUTS Yearly Net Income VS EBIT VS OCF VS FCFGUTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -106.94%, GUTS is not doing good in the industry: 81.18% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -106.94%
ROE N/A
ROIC N/A
ROA(3y)-97.75%
ROA(5y)-92.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GUTS Yearly ROA, ROE, ROICGUTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

Looking at the Gross Margin, with a value of 100.00%, GUTS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for GUTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GUTS Yearly Profit, Operating, Gross MarginsGUTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

GUTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUTS has been increased compared to 1 year ago.
The number of shares outstanding for GUTS has been increased compared to 5 years ago.
The debt/assets ratio for GUTS has been reduced compared to a year ago.
GUTS Yearly Shares OutstandingGUTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
GUTS Yearly Total Debt VS Total AssetsGUTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.90, we must say that GUTS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GUTS (-6.90) is worse than 73.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.9
ROIC/WACCN/A
WACC8.43%
GUTS Yearly LT Debt VS Equity VS FCFGUTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 4.27 indicates that GUTS has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.27, GUTS is doing good in the industry, outperforming 71.51% of the companies in the same industry.
A Quick Ratio of 4.27 indicates that GUTS has no problem at all paying its short term obligations.
GUTS's Quick ratio of 4.27 is fine compared to the rest of the industry. GUTS outperforms 77.96% of its industry peers.
Industry RankSector Rank
Current Ratio 4.27
Quick Ratio 4.27
GUTS Yearly Current Assets VS Current LiabilitesGUTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

GUTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.13%.
The Revenue for GUTS has decreased by -96.91% in the past year. This is quite bad
EPS 1Y (TTM)-59.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.92%
Revenue 1Y (TTM)-96.91%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, GUTS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.23% on average per year.
The Revenue is expected to grow by 450.37% on average over the next years. This is a very strong growth
EPS Next Y-8.53%
EPS Next 2Y23.72%
EPS Next 3Y15.9%
EPS Next 5Y15.23%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y664.32%
Revenue Next 5Y450.37%

3.3 Evolution

GUTS Yearly Revenue VS EstimatesGUTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 100M 200M 300M 400M
GUTS Yearly EPS VS EstimatesGUTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GUTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GUTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GUTS Price Earnings VS Forward Price EarningsGUTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GUTS Per share dataGUTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as GUTS's earnings are expected to grow with 15.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.72%
EPS Next 3Y15.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GUTS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

FRACTYL HEALTH INC

NASDAQ:GUTS (12/29/2025, 8:00:02 PM)

After market: 2.32 -0.05 (-2.11%)

2.37

+0.1 (+4.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-03 2026-03-03/amc
Inst Owners71.46%
Inst Owner Change230.37%
Ins Owners1.52%
Ins Owner Change0.09%
Market Cap324.78M
Revenue(TTM)3.00K
Net Income(TTM)-122.20M
Analysts85.45
Price Target7.59 (220.25%)
Short Float %6.72%
Short Ratio3.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-87.75%
Min EPS beat(2)-120.28%
Max EPS beat(2)-55.23%
EPS beat(4)0
Avg EPS beat(4)-48.37%
Min EPS beat(4)-120.28%
Max EPS beat(4)-0.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.68%
PT rev (3m)11.6%
EPS NQ rev (1m)-0.3%
EPS NQ rev (3m)28%
EPS NY rev (1m)-9.41%
EPS NY rev (3m)-6.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 108261.6
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.94%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-97.75%
ROA(5y)-92.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.35%
Cap/Sales 26233.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.27
Quick Ratio 4.27
Altman-Z -6.9
F-Score2
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)132.87%
Cap/Depr(5y)81.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.92%
EPS Next Y-8.53%
EPS Next 2Y23.72%
EPS Next 3Y15.9%
EPS Next 5Y15.23%
Revenue 1Y (TTM)-96.91%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y664.32%
Revenue Next 5Y450.37%
EBIT growth 1Y-21.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.49%
EBIT Next 3Y-4.97%
EBIT Next 5Y23.95%
FCF growth 1Y-93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.21%
OCF growth 3YN/A
OCF growth 5YN/A

FRACTYL HEALTH INC / GUTS FAQ

What is the fundamental rating for GUTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to GUTS.


Can you provide the valuation status for FRACTYL HEALTH INC?

ChartMill assigns a valuation rating of 0 / 10 to FRACTYL HEALTH INC (GUTS). This can be considered as Overvalued.


How profitable is FRACTYL HEALTH INC (GUTS) stock?

FRACTYL HEALTH INC (GUTS) has a profitability rating of 1 / 10.


What is the financial health of FRACTYL HEALTH INC (GUTS) stock?

The financial health rating of FRACTYL HEALTH INC (GUTS) is 3 / 10.


What is the expected EPS growth for FRACTYL HEALTH INC (GUTS) stock?

The Earnings per Share (EPS) of FRACTYL HEALTH INC (GUTS) is expected to decline by -8.53% in the next year.